LANDIOLOL

Other

Brand names: RAPIBLYK

Intravenous

Mechanism of Action

12.1 Mechanism of Action RAPIBLYK is a selective beta-1-adrenoreceptor antagonist that inhibits the positive chronotropic effects of the catecholamines, epinephrine and norepinephrine, on the heart, where beta-1-receptors are predominantly located. Landiolol does not exhibit any membrane-stabilizing activity or intrinsic sympathomimetic activity at the approved recommend dosage in vitro.

Indications

See full prescribing information

Contraindications

• 4 CONTRAINDICATIONS RAPIBLYK is contraindicated in patients with: Severe sinus bradycardia
• sick sinus syndrome
• including anaphylaxis

FDA Warnings

5 WARNINGS AND PRECAUTIONS Risk of hypotension, bradycardia, and cardiac failure: Monitor for signs and symptoms of cardiovascular adverse effects
3 ) Risk of exacerbating reactive airway disease ( 5
1 Hypotension Patients with hemodynamic compromise, hypovolemia, or on interacting medications are at increased risk of hypotension
2 Bradycardia Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders are at increased risk of bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest

Known Side Effects

4 documented side effects by frequency

Drug Not Working

>10%

Condition Worsened

1-10%

Low Blood Pressure

0.1-1%

Rapid Heart Rate

0.1-1%

Community Discussions

No community discussions found for LANDIOLOL yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous